Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16572419rdf:typepubmed:Citationlld:pubmed
pubmed-article:16572419lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:16572419lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:16572419lifeskim:mentionsumls-concept:C0031809lld:lifeskim
pubmed-article:16572419lifeskim:mentionsumls-concept:C0553580lld:lifeskim
pubmed-article:16572419lifeskim:mentionsumls-concept:C0013089lld:lifeskim
pubmed-article:16572419lifeskim:mentionsumls-concept:C0015133lld:lifeskim
pubmed-article:16572419lifeskim:mentionsumls-concept:C0020823lld:lifeskim
pubmed-article:16572419lifeskim:mentionsumls-concept:C0042679lld:lifeskim
pubmed-article:16572419lifeskim:mentionsumls-concept:C0036043lld:lifeskim
pubmed-article:16572419lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:16572419pubmed:issue1lld:pubmed
pubmed-article:16572419pubmed:dateCreated2006-5-8lld:pubmed
pubmed-article:16572419pubmed:abstractTextThe EUROpean Ewing tumour Working Initiative of National Groups 1999 (EURO-E.W.I.N.G. 99) protocol prescribes six courses of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) as intensive induction chemotherapy for Ewing tumors (ET). Granulocyte-colony stimulating factor (G-CSF) is recommended. Adverse reactions (AR) were evaluated; quality assurance of data collection reviewed.lld:pubmed
pubmed-article:16572419pubmed:languageenglld:pubmed
pubmed-article:16572419pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16572419pubmed:citationSubsetIMlld:pubmed
pubmed-article:16572419pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16572419pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16572419pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16572419pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16572419pubmed:statusMEDLINElld:pubmed
pubmed-article:16572419pubmed:monthJullld:pubmed
pubmed-article:16572419pubmed:issn1545-5009lld:pubmed
pubmed-article:16572419pubmed:authorpubmed-author:ZoubekAndreas...lld:pubmed
pubmed-article:16572419pubmed:authorpubmed-author:LewisIanIlld:pubmed
pubmed-article:16572419pubmed:authorpubmed-author:PaulussenMich...lld:pubmed
pubmed-article:16572419pubmed:authorpubmed-author:MichonJeanJlld:pubmed
pubmed-article:16572419pubmed:authorpubmed-author:OberlinOdileOlld:pubmed
pubmed-article:16572419pubmed:authorpubmed-author:WestonClaireClld:pubmed
pubmed-article:16572419pubmed:authorpubmed-author:CraftAlanAlld:pubmed
pubmed-article:16572419pubmed:authorpubmed-author:JuergensHerbe...lld:pubmed
pubmed-article:16572419pubmed:authorpubmed-author:WhelanJeremyJlld:pubmed
pubmed-article:16572419pubmed:authorpubmed-author:JuergensChris...lld:pubmed
pubmed-article:16572419pubmed:copyrightInfoCopyright 2006 Wiley-Liss, Inc.lld:pubmed
pubmed-article:16572419pubmed:issnTypePrintlld:pubmed
pubmed-article:16572419pubmed:volume47lld:pubmed
pubmed-article:16572419pubmed:ownerNLMlld:pubmed
pubmed-article:16572419pubmed:authorsCompleteYlld:pubmed
pubmed-article:16572419pubmed:pagination22-9lld:pubmed
pubmed-article:16572419pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:16572419pubmed:meshHeadingpubmed-meshheading:16572419...lld:pubmed
pubmed-article:16572419pubmed:meshHeadingpubmed-meshheading:16572419...lld:pubmed
pubmed-article:16572419pubmed:meshHeadingpubmed-meshheading:16572419...lld:pubmed
pubmed-article:16572419pubmed:meshHeadingpubmed-meshheading:16572419...lld:pubmed
pubmed-article:16572419pubmed:meshHeadingpubmed-meshheading:16572419...lld:pubmed
pubmed-article:16572419pubmed:meshHeadingpubmed-meshheading:16572419...lld:pubmed
pubmed-article:16572419pubmed:meshHeadingpubmed-meshheading:16572419...lld:pubmed
pubmed-article:16572419pubmed:meshHeadingpubmed-meshheading:16572419...lld:pubmed
pubmed-article:16572419pubmed:meshHeadingpubmed-meshheading:16572419...lld:pubmed
pubmed-article:16572419pubmed:meshHeadingpubmed-meshheading:16572419...lld:pubmed
pubmed-article:16572419pubmed:meshHeadingpubmed-meshheading:16572419...lld:pubmed
pubmed-article:16572419pubmed:meshHeadingpubmed-meshheading:16572419...lld:pubmed
pubmed-article:16572419pubmed:meshHeadingpubmed-meshheading:16572419...lld:pubmed
pubmed-article:16572419pubmed:meshHeadingpubmed-meshheading:16572419...lld:pubmed
pubmed-article:16572419pubmed:meshHeadingpubmed-meshheading:16572419...lld:pubmed
pubmed-article:16572419pubmed:meshHeadingpubmed-meshheading:16572419...lld:pubmed
pubmed-article:16572419pubmed:meshHeadingpubmed-meshheading:16572419...lld:pubmed
pubmed-article:16572419pubmed:year2006lld:pubmed
pubmed-article:16572419pubmed:articleTitleSafety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial.lld:pubmed
pubmed-article:16572419pubmed:affiliationCoordinating Centre for Clinical Trials (KKS), University of Muenster, Muenster, Germany.lld:pubmed
pubmed-article:16572419pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16572419pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:16572419pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:16572419pubmed:publicationTypeEvaluation Studieslld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16572419lld:pubmed